pharmx ASX RELEASE

ASX Announcement (ASX:PHX)

26/02/2026

CLEANSING NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT

As announced on 23 February 2026, Pharmx Technologies Limited (ACN 000 091 305) (**Pharmx**) agreed to issue new fully paid ordinary shares in Pharmx (**Shares**) to CW Retail Holdings Pty Ltd ATF CW Retail Holdings Trust ABN 68 102 632 384 (a subsidiary of Sigma Healthcare Limited (ASX:SIG)) under the terms of a binding, multi-year strategic alliance (**Agreement**). On 25 February 2026 Pharmx issued 59,950,679 Shares under the Agreement at an issue price of $0.145 per Share.

Pharmx gives notice that:

a) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act 2001 (Cth) (Corporations Act); and

b) this notice is given under section 708A(5)(e) of the Corporations Act;

c) as at the date of this notice, Pharmx has complied with:

   i. the provisions of Chapter 2M of the Corporations Act, as they apply to Pharmx; and

   ii. section 674 of the Corporations Act, as it applies to Pharmx; and

d) as at the date of this notice, there is no information that is ‘excluded information’ within the meanings of sections 708A(7) and 708A(8) of the Corporations Act that is required to be set out in this notice.

ENDS

This announcement has been authorised for lodgement by the Board

For further information contact:
Tom Culver
Chief Executive Officer
investor.relations@pharmx.com.au

About Pharmx Technologies Ltd.

Pharmx is ANZ’s leading pharmacy ordering platform, providing essential infrastructure for seamless ordering and inventory management. By connecting the largest network of pharmacies, suppliers, and technology vendors, Pharmx facilitates approximately $20 billion in transactions annually through its robust, high-availability technology platform—driving efficient operations, seamless connectivity, and valuable insights across its ordering, eInvoicing, and analytics solutions.

Operating in a dynamic and evolving market, Pharmx is positioned for sustained growth, driven by population growth, demographic shifts, and regulatory changes. With a strategic focus on expanding its addressable market, Pharmx leverages its extensive network, proprietary pharmatech solutions, and advanced data capabilities to unlock new revenue opportunities and enhance healthcare outcomes across Australia and New Zealand.

investor.relations@pharmx.com.au
PO Box Q281 Queen Victoria
Building, Sydney, NSW 1230

pharmx.com.au
1300 724 579
ABN: 25 000 091 305
ACN: 000 091 305